A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval
Brian Grunau, Michael Asamoah-Boaheng, Pascal M. Lavoie, Mohammad Ehsanul Karim, Tracy L Kirkham, Paul A. Demers, Vilte Barakauskas, Ana Márquez, Agatha N. Jassem, Sheila F. O’Brien, Steven J. Drews, Scott Haig, Sheldon Cheskes, David A. Goldfarb
Abstract
The optimal dosing interval for severe acute respiratory syndrome coronavirus 2 vaccines remains controversial. In this prospective study, we compared serology results of paramedics vaccinated with mRNA vaccines at the recommended short (17-28 days) vs long (42-49 days) interval. We found that a long dosing interval resulted in higher spike, receptor binding domain, and spike N terminal domain antibody concentrations.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakBetacoronavirusCoronavirusRespiratory systemAntibodyImmunologySevere acute respiratory syndrome coronavirusDosingInternal medicineOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing